SCMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sucampo Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2017 was $41.5 Mil. Sucampo Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2017 was $33.0 Mil. Therefore, Sucampo Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2017 was 125.69%.
The historical rank and industry rank for Sucampo Pharmaceuticals's ROE % or its related term are showing as below:
The historical data trend for Sucampo Pharmaceuticals's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sucampo Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||||
ROE % | Get a 7-Day Free Trial | 12.40 | 13.76 | 18.58 | 39.55 | 14.58 |
Sucampo Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | |
ROE % | Get a 7-Day Free Trial | 24.10 | 39.20 | 10.84 | -722.30 | 125.69 |
For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's ROE % distribution charts can be found below:
* The bar in red indicates where Sucampo Pharmaceuticals's ROE % falls into.
Sucampo Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2016 is calculated as
ROE % | = | Net Income (A: Dec. 2016 ) | / | ( (Total Stockholders Equity (A: Dec. 2015 ) | + | Total Stockholders Equity (A: Dec. 2016 )) | / count ) |
= | 18.487 | / | ( (86.449 | + | 167.099) | / 2 ) | |
= | 18.487 | / | 126.774 | ||||
= | 14.58 % |
Sucampo Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2017 is calculated as
ROE % | = | Net Income (Q: Sep. 2017 ) | / | ( (Total Stockholders Equity (Q: Jun. 2017 ) | + | Total Stockholders Equity (Q: Sep. 2017 )) | / count ) |
= | 41.468 | / | ( (26.348 | + | 39.634) | / 2 ) | |
= | 41.468 | / | 32.991 | ||||
= | 125.69 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2017) net income data. ROE % is displayed in the 30-year financial page.
Sucampo Pharmaceuticals (NAS:SCMP) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
ROE % | (Q: Sep. 2017 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 41.468 | / | 32.991 | ||
= | (Net Income / Revenue ) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (41.468 / 245.064) | * | (245.064 / 376.6135) | * | (376.6135 / 32.991) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 16.92 % | * | 0.6507 | * | 11.4156 |
= | ROA % | * | Equity Multiplier | ||
= | 11.01 % | * | 11.4156 | ||
= | 125.69 % |
With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.
The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:
ROE % | (Q: Sep. 2017 ) | ||||||||
= | Net Income | / | Total Stockholders Equity | ||||||
= | 41.468 | / | 32.991 | ||||||
= | (Net Income / Pre-Tax Income) | * | (Pre-Tax Income / Operating Income) | * | (Operating Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (41.468 / 70.284) | * | (70.284 / 84.8) | * | (84.8 / 245.064) | * | (245.064 / 376.6135) | * | (376.6135 / 32.991) |
= | Tax Burden | * | Interest Burden | * | Operating Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 0.59 | * | 0.8288 | * | 34.6 % | * | 0.6507 | * | 11.4156 |
= | 125.69 % |
Note: The net income data used here is four times the quarterly (Sep. 2017) net income data. The Revenue data used here is four times the quarterly (Sep. 2017) revenue data. The same rule applies to Pre-Tax Income and Operating Income. * In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Greenleaf | officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Maureen Oconnell | director | |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jones W. Bryan | officer: Sr. Vice Pres., BD & Licensing | C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Peter A Kiener | officer: Chief Science Officer | 40 GUEST STREET, BOSTON MA 02135 |
John Johnson | director | DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101 |
Peter P. Pfreundschuh | officer: CFO | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Paul R Edick | director | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010 |
Thomas J Knapp | other: Former Officer | 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239 |
William Ashton | director | C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073 |
Timothy I Maudlin | director | 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347 |
Nantahala Capital Management, Llc | 10 percent owner | 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840 |
Mariam E Morris | officer: Chief Acctg. Officer, Treas. | C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814 |
From GuruFocus
By gurufocus 10qk • 05-10-2010
By gurufocus 10qk • 11-03-2010
By Omar Venerio Omar Venerio • 11-01-2017
By gurufocus 10qk • 03-08-2011
By gurufocus 10qk • 08-05-2010
By gurufocus • 08-08-2009
By gurufocus 10qk • 11-06-2009
By gurufocus • 05-12-2009
By alicet236 alicet236 • 10-21-2013
By reports.droy reports.droy • 03-04-2015
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.